The latest medical insurance information in 2024: The maximum number of courses of treatment that ixazomib will be reimbursed for

Ixazomib (Ixazomib) has been sold in China under the trade name of Ixazomib Citrate Capsules, and has been included in the scope of Class B medical insurance. Reimbursement is limited to adult patients with multiple myeloma who have received at least one previous treatment. Different Reimbursement ratios vary by region, and the post-reimbursement price may also be different. The maximum number of reimbursed treatments may vary depending on the country, medical insurance plan, and treatment guideline. For specific medical insurance related information, patients can consult the local medical insurance bureau or hospital.

Ixazomib is an oral proteasome inhibitor used to treat multiple myeloma. Ixazomib is the first oral second-generation proteasome inhibitor approved by the U.S. Food and Drug Administration (FDA) in combination with dexamethasone and lenalidomide for patients who have received one prior treatment, allowing patients to take exclusively oral dosing, which has been shown to have a progression-free survival benefit. Ixazomib was approved based on results from the Phase III TOURMALINE-MM1 study, a global, double-blind, randomized study in patients with relapsed/refractory multiple myeloma.

For domestically marketed ixazomib original drugs, common capsule preparations may cost more than 10,000 yuan per box, which is relatively expensive. However, for ixazomib original drugs sold overseas, each box costs more than 10,000 U.S. dollars (the price may fluctuate due to exchange rates). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.